title: Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells.
abstract: A comparison of the effects of various phosphodiesterase (PDE) inhibitors upon cellular cAMP levels was undertaken in human neuroblastoma SH-SY5Y cells. When inhibitors such as rolipram and Ro 20 1724 (selective for the low Km cAMP-specific PDE) were used, cAMP levels were seen to rise dramatically under basal (< or = 60 fold) or forskolin-stimulated (< or = 200 fold) conditions. However, the non-selective PDE inhibitor isobutylmethylxanthine (IBMX) was 7-18% as effective as these other agents even at 1 mM. The poor efficacy of IBMX was not attributable to concomitant increases in cGMP, to alterations in cAMP egress or to a lack of sensitivity of the cellular PDEs to IBMX inhibition. In additivity experiments, IBMX potently and rapidly reduced cAMP that had accumulated after rolipram treatment. The fact that the agonist 2-chloroadenosine can enhance cAMP accumulation in these cells, and that cAMP elevated by rolipram or forskolin can be reduced by adenosine deaminase and theophylline suggest that cell-derived adenosine enhances cAMP in these cells in an autocrine fashion. Since IBMX is an adenosine receptor antagonist, it is suggested that its blockade of endogenous adenosine effects is at least partly responsible for its poor response when compared to other PDE inhibitors which are weaker adenosine receptor antagonists. These results forewarn against assuming that similar levels of cAMP accumulate after application of PDE inhibitors in these cells.
authors.affiliation: Department of Pharmacology and Therapeutics, University of Leicester, U.K.
authors.forename: A J
authors.initials: AJ
authors.lastname: Morgan
authors.forename: K J
authors.initials: KJ
authors.lastname: Murray
authors.forename: R A
authors.initials: RA
authors.lastname: Challiss
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology*; D015762:2-Chloroadenosine / Q000494:pharmacology; D000241:Adenosine / Q000037:antagonists & inhibitors; D000067956:Adenylyl Cyclase Inhibitors; D002460:Cell Line / Q000187:drug effects / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000032:analysis*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009447:Neuroblastoma / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology; D020889:Rolipram; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D010726:Phosphodiesterase Inhibitors; D011760:Pyrrolidinones; D015762:2-Chloroadenosine; D005576:Colforsin; D000242:Cyclic AMP; D020889:Rolipram; D000241:Adenosine; D015056:1-Methyl-3-isobutylxanthine